Target intelligence / Profile preview

Pathogenic bacteria in gastrointestinal tract

Molecular classification
Other
01

Overview

Pathogenic bacteria in the gastrointestinal tract are diverse groups of microorganisms that cause disease by colonizing the gut mucosa and producing toxins or invading host tissues. Notable examples include Escherichia coli pathotypes such as enterotoxigenic E. coli (ETEC), enterohemorrhagic E. coli (EHEC), enteropathogenic E. coli (EPEC), enteroinvasive E. coli (EIEC), Shigella species causing dysentery, Salmonella species causing gastroenteritis and typhoid fever, Listeria monocytogenes affecting immunocompromised individuals, Campylobacter jejuni causing diarrhea and abdominal pain[1][3][5]. These organisms are transmitted via contaminated food or water and direct contact with infected individuals or animals[1][3]. They can cause symptoms ranging from mild diarrhea to life-threatening conditions such as hemolytic-uremic syndrome due to EHEC infection. Therapeutic targeting involves antibiotics tailored to the specific pathogen’s susceptibility profile and supportive care measures like hydration therapy[2][4]. The emergence of antibiotic-resistant strains poses significant challenges in treatment. *Note: This entry describes a group rather than an individual molecule/receptor.*

Other names
Gastrointestinal pathogensEnteric pathogensGI tract pathogenic bacteriaIntestinal pathogenic bacteria
02

Mechanism of action

Inhibition of bacterial cell wall synthesis (e.g., beta-lactams), inhibition of protein synthesis (e.g., macrolides), inhibition of DNA replication (e.g., fluoroquinolones), disruption of cell membrane function[1][4]. Vaccines may induce immune response to prevent infection.

03

Biological functions

InfectionColonizationToxin productionImmune evasion
04

Disease associations

Infection (gastroenteritis, foodborne illness)Inflammation (e.g., colitis)Hemolytic-uremic syndrome (HUS)Sepsis
05

Safety considerations

Antibiotic resistance is a major concern with many GI bacterial pathogens.Overuse can lead to Clostridioides difficile infection and disruption of normal microbiota[1][4].Some infections can progress to severe systemic illness if untreated.Vaccines may have limited coverage against all strains/serotypes.
06

Interacting drugs

Antibiotics

5 more in the full profile.

07

Biomarkers

Fecal leukocytes and occult blood for invasive diseasePCR or culture identification from stool samples for specific pathogens like E. coli O157:H7 or Salmonella spp.Serological markers for systemic complications[2][3]

Beyond the preview

Go deeper on Pathogenic bacteria in gastrointestinal tract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pathogenic bacteria in gastrointestinal tract.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call